Home › Melanoma › Oklahoma › Tulsa
Melanoma clinical trials in Tulsa, OK
5 studies for Melanoma are looking for participants at sites in and around Tulsa (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RecruitingPhase 3
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
Pan-tumor MRD Study
RecruitingObservational study
- Oklahoma Cancer Specialists and Research Institute (OCSRI), Tulsa
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Saint Francis Children's Hospital, Tulsa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Tulsa
BostonGene and Exigent Genomic INsight Study
RecruitingObservational study
- Oklahoma Cancer Specialists and Research Institute, Tulsa
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN32 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Salt Lake City, UT21 studies
- Columbus, OH21 studies
- Atlanta, GA21 studies
- Durham, NC20 studies
Other studies in Tulsa
- Heart Failure9 studies
- Overweight6 studies
- Ischemic Stroke5 studies
- Obesity5 studies
- Aortic Valve Stenosis4 studies
- Depression4 studies
- Endometrial Cancer4 studies
- Cancer (all types)4 studies
- Breast Cancer4 studies
- Parkinson's Disease4 studies
- Ovarian Cancer4 studies
- Non-Small Cell Lung Cancer4 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.